Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EPR Properties (EPR) vs Johnson & Johnson (JNJ) Price & Performance

EPR PropertiesTrade
Johnson & JohnsonTrade

Price performance (Past 24H)

Key statistics

EPR Properties vs Johnson & Johnson — how do they compare? EPR Properties trades at $61.73 (market cap $4.60B), while Johnson & Johnson trades at $248.59 (market cap $594.63B). The key difference: Johnson & Johnson is far larger — about 129.3× EPR Properties's market cap, and EPR Properties pays the higher dividend (6.19%). Which is the better fit depends on your goals.

EPRJNJ
Market Cap
$4.60B$594.63B
Sector
Real EstateHealth
52-Week High
$60.81$267.24
52-Week Low
$48.71$162.98
Enterprise Value
$7.66B$627.57B
Dividend Yield
6.19%2.17%
Volume
6,156,228

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EPR Properties

EPR Properties (EPR) trades at $61.80, up 3.8% over 24 hours, with a bullish technical signal from moving averages and a consensus analyst price target of $63.25. The REIT maintains strong profitability with a 39.93% net income margin and 10.68% ROE, supported by recent earnings beats and a strategic shift toward experiential assets like the $315 million Six Flags acquisition. Monthly dividends of $0.31 provide a steady income stream, with Q2 2026 earnings results due July 29, 2026.

Outlook remains positive due to high occupancy, dividend yield, and portfolio diversification, but risks include reliance on consumer spending and potential interest rate impacts. Analyst sentiment is mixed with a hold-heavy consensus, suggesting cautious optimism for income-focused investors amid stable fundamentals.

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $249.42, down 1.75% over 24 hours, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q2 2026 EPS of $2.90, beating estimates, and raised full-year guidance. Revenue grew 6.6% annually, supported by strong pharmaceutical sales. Analyst consensus is bullish with a $281 price target, and the stock offers a stable dividend with recent payouts of $1.34 per share.

Outlook remains positive due to robust fundamentals, innovation in medtech and pharmaceuticals, and dividend king status. Risks include patent expirations, regulatory pressures, and macroeconomic volatility. The current valuation at P/E 28.66 may limit near-term upside, but long-term growth prospects appear solid.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EPR Properties

EPR Properties is a REIT specializing in experiential real estate, including movie theaters and leisure destinations like ski resorts and water parks across the US and Canada.

Read more on EPR

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ